65,437 trials
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
Migraine · Episodic Migraine · Phonophobia
Primary: Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to Intensity — 33; 17; 17 Participants
SARS-CoV-2 Infection
Primary: Incidence of Adverse Drug Reactions — 423; 6 Participants
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 3; 7; 11; 11 Participants
Advanced Solid Tumors
Primary: Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) — 288.55; 105.8 μg·h/L/mg
Atopic Dermatitis
Primary: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade…
Attention Deficit/Hyperactivity Disorder · Inattention
Primary: ADHD Symptoms — 27.7; 27.5; 27.7; 34.6 score on a scale
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 2; 9; 12; 12 Participants
Lung Cancer · Behavior
Primary: Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants — 88; 68; 64 % of lcs appointment attendance
Recurrent Herpes Labialis
Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716
Eveningness/Sleep
Primary: Total Sleep Time (TST) Average on Weeknights Via Daily Sleep Diary — 24.72; 13.02 Minutes — p=0.34
Social Exclusion · Prejudice, Racial · Prejudice
Primary: School Belonging Scale — 4.72; 4.72 score on a scale
Hospice · Psilocybin · Demoralization
Primary: Number of Participants Screened Per Study Period — 4607 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: To Evaluate the Effect of Mitiperstat (AZD4831) as Compared to Placebo on the Time to First COPD Composite Exacerbation (CompEx) Event in Patients With Moderate to…